Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in ...

Mutant selectivity remains one of drug discovery’s hardest problems. New preclinical research applying quantum chemistry to JAK2V617F illustrates how detailed molecular analysis can inform more ...

NEW YORK – Cogent Biosciences expects the US Food and Drug Administration to decide whether to approve its KIT D816V tyrosine kinase inhibitor bezuclastinib as a treatment for non-advanced systemic ...

Over the past two decades, advances in understanding the pathogenesis and therapeutic vulnerabilities of myeloid cancers have led to increasingly precise and rational treatment strategies. Few ...

The MarketWatch News Department was not involved in the creation of this content. DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Eilean Therapeutics announced the advancement of ZE74-0282 into ...

CAMBRIDGE, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, today announced that it will unveil the ...

Background: Left ventricular thrombus (LVT) is often associated with anterior myocardial infarction (MI) and reduced ejection fraction (EF). However, it could be present in patients with no prior ...

Case: A 60-year-old man with history of hypertension, diabetes, and remote history of unprovoked lower extremity DVT presented with dyspnea for 3 days and chest pain for 1 day. Initial ECG revealed ...

ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...

VGT-1849B, a selective JAK2 inhibitor, targets JAK2 mRNA to reduce protein production, potentially improving safety profiles over existing therapies. Polycythemia vera is a rare myeloproliferative ...